Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation

Brain

Volumn 137, Issue 12, 2014, Pages 3235-3247

  Fishbein, Ianai ^a   Kuo, Yien Ming ^a   Giasson, Benoit I ^b   Nussbaum, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Alpha synuclein; Gaucher disease; Lysosomal protein degradation; Mouse model; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSYLCERAMIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BRAIN CELL CULTURE; CELL CULTURE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME ACTIVITY; GASTROINTESTINAL DISEASE; GAUCHER DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HALF LIFE TIME; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; INTESTINE INNERVATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOTOR SYSTEM; MOUSE; MOUSE STRAIN; NERVE CELL CULTURE; NONHUMAN; PARKINSON DISEASE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; STEADY STATE; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; WILD TYPE MOUSE; 129 MOUSE; ANIMAL; COMPLICATION; DISEASE MODEL; GENETICS; GENOTYPE; HETEROZYGOTE; METABOLISM; MUTATION; PHENOTYPE;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; GAUCHER DISEASE; GENE EXPRESSION; GENOTYPE; GLUCOSYLCERAMIDASE; HETEROZYGOTE; MICE, 129 STRAIN; MICE, TRANSGENIC; MUTATION; PARKINSON DISEASE; PHENOTYPE;

EID: 84922266926     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu291     Document Type: Article

References (47)

1. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351: 1972-7.
2. Alvarez-Castelao B, Castano JG. Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. Cell Mol Life Sci 2011; 68: 2643-54.
3. Argyriou A, Dermentzaki G, Papasilekas T, Moraitou M, Stamboulis E, Vekrellis K, et al. Increased dimerization of alpha-synuclein in erythro-cytes in Gaucher disease and aging. Neurosci Lett 2012; 528: 205-9.
4. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012; 32: 13454-69.
5. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM. Degradation of alpha-synuclein by proteasome. J Biol Chem 1999; 274: 33855-8.
6. Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 2013; 62: 1-7.
7. Clough RL, Dermentzaki G, Haritou M, Petsakou A, Stefanis L. Regulation of alpha-synuclein expression in cultured cortical neurons. J Neurochem 2011; 117: 275-85.
8. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011; 91: 1161-218.
9. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autop-hagy. Science 2004; 305: 1292-5.
10. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol 2011; 69: 940-53.
11. Deleidi M, Maetzler W. Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis 2012; 2012: 391438.
12. Dermentzaki G, Dimitriou E, Xilouri M, Michelakakis H, Stefanis L. Loss of beta-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS One 2013; 8: e60674.
13. Farfel-Becker T, Vitner E, Dekel H, Leshem N, Enquist IB, Karlsson S, et al. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet 2009; 18: 1482-8.
14. Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 2011; 118: 821-39.
15. Fishbein I, Segal M. Miniature synaptic currents become neurotoxic to chronically silenced neurons. Cereb Cortex 2007; 17: 1292-306.
16. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012; 72: 455-63.
17. Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 2000; 59: 528-33.
18. Ginns EI, Mak SK, Ko N, Karlgren J, Akbarian S, Chou VP, et al. Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol Genet Metab 2014; 111: 152-62.
19. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008; 372: 1263-71.
20. Korczyn AD, Gurevich T. Parkinson's disease: before the motor symptoms and beyond. J Neurol Sci 2010; 289: 2-6.
21. Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010; 19: 1633-50.
22. Lesage S, Anheim M, Letournel F, Bousset L, Honore A, Rozas N, et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013; 73: 12.
23. Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J Neurosci 2004; 24: 7400-9.
24. Liu Y, Suzuki K, Reed JD, Grinberg A, Westphal H, Hoffmann A, et al. Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc Natl Acad Sci USA 1998; 95: 2503-8.
25. Machiya Y, Hara S, Arawaka S, Fukushima S, Sato H, Sakamoto M, et al. Phosphorylated alpha-synuclein at Ser-129 is targeted to the prote-asome pathway in a ubiquitin-independent manner. J Biol Chem 2010; 285: 40732-44.
26. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37-52.
27. Mezey E, Dehejia AM, Harta G, Tresser N, Suchy SF, Nussbaum RL, et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry 1998; 3: 493-9.
28. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y, et al. Systemic inflammation in glucocerebrosidase-deficient mice with minimal gluco-sylceramide storage. J Clin Invest 2002; 109: 1215-21.
29. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996; 89: 691-4.
30. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
31. Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, et al. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 2013; 80: 1062-4.
32. Rideout HJ, Dietrich P, Savalle M, Dauer WT, Stefanis L. Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. J Neurochem 2003; 84: 803-13.
33. Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 2011; 108: 12101-6.
34. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-61.
35. Siebert M, Sidransky E, Westbroek W. Glucocerebrosidase is shaking up the synucleinopathies. Brain 2014; 137 (Pt 5): 1304-22.
36. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-12.
37. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
38. Sun Y, Liou B, Xu YH, Quinn B, Zhang W, Hamler R, et al. Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem 2012; 287: 4275-87.
39. Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, et al. Gaucher disease and parkinsonism: a pheno-typic and genotypic characterization. Mol Genet Metab 2001; 73: 313-21.
40. Urban DJ, Zheng W, Goker-Alpan O, Jadhav A, Lamarca ME, Inglese J, et al. Optimization and validation of two miniaturized glucocerebrosi-dase enzyme assays for high throughput screening. Comb Chem High Throughput Screen 2008; 11: 817-24.
41. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008; 283: 23542-56.
42. Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol 2008; 116: 37-46.
43. Waxman EA, Giasson BI. A novel, high-efficiency cellular model of fibril-lar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J Neurochem 2010; 113: 374-88.
44. Westbroek W, Gustafson AM, Sidransky E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 2011; 17: 485-93.
45. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004; 82: 192-207.
46. Wu KP, Kim S, Fela DA, Baum J. Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. J Mol Biol 2008; 378: 1104-15.
47. Yap TL, Velayati A, Sidransky E, Lee JC. Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab 2013; 108: 56-64.